SARMs lower the body’s own testosterone. In the human trials that measured it, LGD-4033 lowered total testosterone in a dose-dependent way in a 21-day trial of 0.1–1 mg/day (Basaria 2013) and ostarine lowered it at 1–3 mg/day (Dalton 2011). In the LGD-4033 trial, hormone levels were back to baseline by day 56, five weeks after the last dose, without any treatment.
No study has tested post-cycle therapy (PCT) after SARMs. So “do I need PCT?” has no answer from trials. It can only be measured, with a blood test. This guide covers what suppression is, what each compound does to testosterone, what PCT drugs have been studied, the SERMs compared side by side, and how bloodwork fits in. Every claim links to its source.
Want to see your own timeline? The PCT & Bloodwork Planner shows when each compound is cleared, what the studies say on suppression and which markers they tracked.
What PCT is, and what suppression means
Testosterone is controlled by a hormone chain: the hypothalamus releases GnRH, the pituitary answers with LH and FSH, and the testes make testosterone (driven by LH) and sperm (driven by FSH). When androgens rise, the brain turns the chain down. That drop is what “suppression” means. Strong androgen use can switch it off completely: in steroid users, it shut down the body’s own testosterone production and sperm production (Smit 2021, HAARLEM study).
SARMs act on the same androgen receptor, so the same feedback applies. The trials show it as falling total testosterone, SHBG and, at higher doses, FSH and free testosterone.
Post-cycle therapy (PCT) means drugs taken after a cycle to restart the chain: SERMs such as clomiphene and tamoxifen, hCG, and sometimes aromatase inhibitors. A 2026 review found the evidence for PCT limited and mostly observational, and noted that most users recover on their own (Smit 2026). A UK clinic study described PCT as “illicit, ill-defined, and not recommended” (Grant 2023).
Do SARMs need PCT? The evidence for each compound
This table uses the suppression data in our compound records. “Score” is Sarmguide’s 0–3 suppression score (0 = none reported, 3 = marked), based on the cited studies.
| Compound | What studies found on testosterone | Evidence | Score |
|---|---|---|---|
| Ostarine (enobosarm) | Older men on 1–3 mg/day for 86 days: total testosterone fell 6.4–7.4 nmol/L vs placebo; SHBG fell on 3 mg; free testosterone, LH and FSH did not change significantly (Dalton 2011). A 14-day Phase 1 study up to 30 mg/day found dose-dependent drops in SHBG and total testosterone (Phase 1 data, cited in the EMERALD protocol). | Trial | 2 |
| LGD-4033 (ligandrol) | Healthy young men, 0.1–1.0 mg/day for 21 days: dose-dependent fall in total testosterone and SHBG; FSH and free testosterone fell at 1.0 mg. Back to baseline by day 56 (Basaria 2013). One user on 10 mg/day with MK-677 for 5 weeks: total testosterone −62%, free testosterone −86% (case report, 2022). | Trial; case report | 3 |
| RAD-140 (testolone) | No trial in men. In young male monkeys, 28 days lowered testosterone by roughly two-thirds (Miller 2011). In the Phase 1 trial in women, SHBG fell in every patient measured (2022). A man developed low testosterone and breast growth after supplements that contained RAD-140 with other drugs (case report, 2024). | Animal; case report | 2 |
| S-23 | Studied in rats as a male contraceptive: it cut LH by more than half at doses above 0.1 mg/day, and with estradiol stopped sperm production in 4 of 6 rats. Fertility fully returned 100 days after stopping (Jones 2009). | Animal | 2 |
| S4 (andarine) | Not measured in a trial. In castrated rats, it lowered LH and FSH in a dose-dependent way (Gao 2005). | Animal | 2 |
| YK-11 | We found no study in people or animals that measured testosterone, LH or FSH with YK-11. | Not established | Not scored |
| MK-677 (not a SARM) | 8-week trial in obese men: total testosterone lower than placebo, but no change in the testosterone/SHBG ratio, LH or FSH (1999). | Trial | 1 |
| Cardarine (not a SARM) | Not a hormone and not an androgen-receptor drug. The human trials did not report testosterone. | None in humans | 0 |
Source: Sarmguide compound database.
Two things make the trial numbers a floor rather than a ceiling. First, dose: the LGD-4033 and ostarine trials used 0.1–3 mg/day, while the case report above used 10 mg/day of LGD-4033. Second, product quality: when 44 products sold online as SARMs were tested in 2017, only 52% contained a SARM and only 41% contained the amount on the label (Van Wagoner 2017). A result after a cycle reflects whatever was actually in the bottle.
More on single compounds: Ostarine PCT, LGD 4033 PCT, RAD140 PCT, RAD-140 suppression, ostarine suppression, YK-11 suppression and MK-677 as PCT.
How recovery works without PCT
The best SARM data point is the LGD-4033 trial: after 21 days at up to 1 mg/day, hormones and lipids returned to baseline within five weeks of stopping (Basaria 2013). Nobody has published recovery data after longer or higher-dose SARM use.
Recovery after anabolic steroids has been studied more, and steroids suppress harder than the SARM doses in trials:
- In the HAARLEM study of 100 amateur athletes, testosterone was back to baseline within 3 months of stopping in most men, but sperm counts took about a year. At the end, 11% still had low testosterone (Smit 2021).
- In 641 men at a UK clinic, only 48.2% had fully normal LH, FSH and testosterone on a single blood test taken up to 36 months after stopping. Men who had used more different steroids were less likely to have recovered (Grant 2023).
What has been studied for PCT
| Approach | How it works | Best evidence after a cycle | What it found |
|---|---|---|---|
| Clomiphene (Clomid) | SERM: blocks estrogen feedback in the brain, so LH and FSH rise | Retrospective study, 79 men after up to 6 months of steroids (İbis 2026) | Clomiphene 25 mg/day, alone or with hCG, sped up hormone recovery vs no treatment, but all groups were normal by month 6. Normal sperm at 12 months: 87.5% (clomiphene + hCG), 69.2% (clomiphene), 58.6% (no treatment). |
| Enclomiphene | One isomer of clomiphene; same mechanism | None. Trials were in men with secondary hypogonadism | Raised testosterone and kept sperm counts in Phase 3 trials (EMA 2018). A 2026 review says it has not been validated in steroid-induced hypogonadism (Bandura 2026). |
| Tamoxifen (Nolvadex) | SERM: blocks estrogen feedback; also raises SHBG | None | In 10 healthy men, testosterone rose about 40% and LH about 70% over 2 weeks (Birzniece 2010). Strong trial evidence for preventing drug-induced breast growth in men (Boccardo 2005). |
| hCG | Acts like LH on the testes directly | Same 79-man study, combined with clomiphene (İbis 2026) | Clomiphene + hCG gave the best semen recovery and testicular volume. hCG is banned in sport under WADA S2 (WADA 2026). |
| Anastrozole (aromatase inhibitor) | Lowers estradiol, so LH and testosterone rise | None | Raised testosterone in older men (Leder 2004), but lowered spine bone density over a year (Burnett-Bowie 2009). |
| Any self-reported PCT | Mixed | 641 men at a UK clinic (Grant 2023) | PCT was linked with faster recovery (median 13 vs 26 weeks), but only in men who had stopped steroids within the previous 3 months. |
The SERMs compared (plus anastrozole)
| Enclomiphene | Clomiphene (Clomid) | Tamoxifen (Nolvadex) | Anastrozole (Arimidex) | |
|---|---|---|---|---|
| Type | SERM (trans-isomer of clomiphene) | SERM (mix of two isomers) | SERM | Aromatase inhibitor |
| Approved for | Nothing: FDA complete response letter in 2015 (BioSpace), EU refusal in 2018 (EMA) | Ovulation problems in women (FDA 1967); off-label in men (FDA) | Breast cancer in women and men (FDA 1977) (FDA) | Breast cancer in postmenopausal women (FDA 1995) (FDA) |
| Effect on testosterone in men | Raised it into the normal range in most trial patients; LH, FSH and sperm counts kept | Raised testosterone, LH and FSH across 19 studies (Huijben 2022) | Testosterone +40%, LH +70% in healthy men; SHBG up too | Raised testosterone by lowering estradiol |
| Half-life | ~8–10 h | Two parts: enclomiphene hours; zuclomiphene builds up and lingers for weeks | ~5–7 days (main metabolite ~14 days) | ~50 h |
| Main safety signals | Blood clots (4 events in trials), blurred vision, raised hematocrit and PSA (EMA) | Visual symptoms that can be lasting (label); mood changes and estradiol rise (Krzastek 2019); lower HDL (Soares 2018) | Blood clots and stroke, loss of libido and impotence in men, liver changes (label) | Bone loss, lower insulin sensitivity (Gibb 2016) |
| Trials after SARMs | None | None (observational data after steroids) | None | None |
| Sport | Banned at all times, WADA S4.2 | Banned at all times, WADA S4.1 | ||
Enclomiphene vs clomiphene. Clomiphene contains both isomers. The zuclomiphene part builds up: in men on long-term clomiphene its blood level was about 20 times that of enclomiphene (Helo 2017), and after 30 days of use it stayed in urine for 121 to more than 261 days (Miller 2019). When 66 men switched from clomiphene to enclomiphene at one clinic, they reported fewer side effects (Saffati 2024). No randomized head-to-head trial exists.
Nolvadex vs Clomid. No trial has compared them for recovery after SARMs or steroids. The observational steroid data are almost all for clomiphene. Tamoxifen has the strongest evidence for one specific job: preventing drug-induced breast growth.
Doses used in studies (history, not a plan)
These are the doses the cited studies used and the people they were tested in. None of them tested recovery after SARMs.
| Compound | Dose in the study | Who | How long | Source |
|---|---|---|---|---|
| Clomiphene | 25 mg/day, alone or with hCG 1,500 IU three times a week | 79 men after up to 6 months of steroids | Followed 12 months | İbis 2026 |
| Clomiphene | 50 mg/day | 12 healthy men | 30 days | Miller 2019 |
| Clomiphene | 50 mg/day | 78 obese men with low testosterone | 12 weeks | Soares 2018 |
| Enclomiphene | 12.5 mg/day, raised to 25 mg/day if testosterone stayed low | Overweight men with secondary hypogonadism | 16 weeks | EMA 2018 |
| Tamoxifen | 10 and 20 mg/day | 10 healthy men | 2-week course at both doses | Birzniece 2010 |
| Tamoxifen | 20 mg/day | 114 men with prostate cancer on bicalutamide | 48 weeks | Boccardo 2005 |
| Anastrozole | 1 mg/day or 1 mg twice a week | 37 men aged 62–74 with low testosterone | 12 weeks | Leder 2004 |
How to tell whether you are suppressed: bloodwork
Suppression is a lab finding. In the trials it was found in blood tests, not by asking how people felt. The markers the studies used:
- Total testosterone, measured fasting in the morning and repeated if low, as the Endocrine Society recommends for diagnosis (Bhasin 2018).
- LH and FSH, which show whether the brain’s signal is switched down: low testosterone with low or normal LH is the pattern of secondary hypogonadism (FDA 2022).
- SHBG and free testosterone. SARMs lower SHBG, which pulls total testosterone down on paper; the guideline advises a free testosterone test when SHBG is altered (Bhasin 2018).
- HDL, liver enzymes and bilirubin, which changed in the SARM trials and case reports.
Timing. A test taken while a compound is still in the body reflects the compound. After five half-lives about 3% is left (StatPearls). With the half-lives in our records, that is roughly 5–8 days for LGD-4033 (24–36 h), 3–5 days for ostarine (14–24 h) and about 9 days for RAD-140 (~45 h, measured in women). The HAARLEM study tested before the cycle, at its end, 3 months after it, and one year after the start (Smit 2021).
The full guide, with reference ranges and what each marker means, is on SARMs bloodwork. For testosterone testing in general, see low testosterone blood test.
How much time off between SARM cycles?
“Time on equals time off” and “time on equals time off plus PCT” are rules of thumb. No study has tested either. What the data do say about recovery time:
- LGD-4033: hormones back to baseline five weeks after a 21-day, low-dose course (Basaria 2013).
- Steroids: testosterone back within about 3 months for most men, sperm after about a year, and 11% still low at one year (Smit 2021).
Some people use a lab-based rule instead of a calendar: they wait until testosterone, LH, FSH, lipids and liver enzymes are back to their own pre-cycle values. That only works with a baseline test taken before the first cycle.
Natural PCT: what the evidence says
No over-the-counter “natural PCT” product has been tested for recovery after SARMs. A review of 50 “testosterone booster” supplements found that 90% claimed to boost testosterone, but only 24.8% had published data supporting the claim, and 10.1% contained ingredients with data suggesting the opposite (Clemesha 2020).
The ingredients most often cited, and what the cited studies actually were:
| Ingredient | Study | What it found | Limits |
|---|---|---|---|
| Resveratrol | Mice, 50 mg/kg for 28 days (Shin 2008) | Blood testosterone +51.6% | Animal study |
| Fenugreek extract | 50 men aged 35–65, 12 weeks (Maheshwari 2017) | Free testosterone up to 46% higher in 90% of men | One arm, open label, no placebo |
| Tongkat ali | 63 moderately stressed adults, 4 weeks, placebo-controlled (Talbott 2013) | Salivary cortisol −16%, salivary testosterone +37% | Not in suppressed men; saliva, not blood |
None of these was tested in men recovering from SARMs or steroids.
Side effects of the PCT drugs themselves
| Drug | Main reported side effects | Evidence |
|---|---|---|
| Clomiphene | Visual symptoms that increase with dose and duration and can be prolonged; the label says to stop and have the eyes checked (label). Of men treated for more than 3 years, 8% reported side effects, mainly mood changes, blurred vision and breast tenderness (Krzastek 2019). Lower HDL (Soares 2018). | Trial; observational |
| Enclomiphene | Headache, hot flushes, nausea, muscle spasm; four blood-clot events in trials, which EMA cited when refusing approval (EMA 2018). | Trial |
| Tamoxifen | Blood clots and stroke; loss of libido and impotence have led some men to stop; liver enzyme changes and, rarely, serious liver injury (label). Hot flushes at 5 mg/day or more (Fradet 2007). | Trial |
| Anastrozole | Lower spine bone density over one year (Burnett-Bowie 2009); lower insulin sensitivity in 6 weeks (Gibb 2016); more body fat and lower sexual function when estrogen is very low (Finkelstein 2013). | Trial |
Two young men developed cholestatic liver injury after a few weeks of ligandrol and/or ostarine followed by post-cycle substances. The authors could not separate the two: they concluded that the SARMs and/or the PCT substances may cause cholestatic liver injury, and flagged supra-therapeutic doses and the lack of monitoring (Koller 2021).
Where to buy PCT compounds
Tamoxifen, clomiphene and anastrozole are prescription medicines in the US, and enclomiphene is not approved anywhere. All four are banned in sport. Our current pick for these compounds is SwissChems, which publishes third-party lab results per batch; the reasons are on Buy PCT and in our SwissChems review.
Bottom line
SARMs suppress testosterone in a dose-dependent way, and in the one trial that followed people after stopping, it came back by itself within five weeks. Beyond that, PCT after SARMs is untested. The SERMs raise testosterone in other groups of men and carry their own risks. A blood test after the compound has cleared shows where you actually stand. Fact sheets: enclomiphene, clomiphene, tamoxifen, anastrozole. All compounds: SARMs database.
Frequently asked questions
Do SARMs need PCT?
Unknown; PCT never testedEvidence: Trial
SARMs lowered testosterone in trials: LGD-4033 at 0.1–1 mg/day and ostarine at 1–3 mg/day. In the LGD-4033 trial, hormones were back to baseline five weeks after stopping without treatment; higher doses and longer use have not been studied.
What is the best PCT for SARMs?
No evidence-based bestEvidence: Human data
No PCT has been tested after SARMs; after steroids, the most-studied option is clomiphene, alone or with hCG, in observational studies. Each drug has its own risks: visual symptoms with clomiphene, blood clots with tamoxifen and enclomiphene.
Do you need PCT after ostarine?
UnknownEvidence: Trial
In older men, 1–3 mg/day for 86 days lowered total testosterone by about 6–7 nmol/L vs placebo, while free testosterone, LH and FSH did not change significantly. Recovery was not reported, and PCT after ostarine has not been studied.
Do you need PCT after RAD-140?
Unknown; not measured in menEvidence: Animal
No trial has measured testosterone in men taking RAD-140; in young male monkeys, 28 days lowered it by about two-thirds. PCT after RAD-140 has not been studied.
Does MK-677 or cardarine need PCT?
Not androgen-receptor drugsEvidence: Trial
In an 8-week trial in obese men, MK-677 lowered total testosterone vs placebo but did not change LH, FSH or the testosterone/SHBG ratio. Cardarine trials did not report testosterone.
Is Nolvadex or Clomid better for SARMs PCT?
Never comparedEvidence: Trial
No trial has compared them for recovery after SARMs or steroids, and the observational steroid data are mostly for clomiphene. Both raise LH and testosterone in men; tamoxifen has strong trial evidence for preventing drug-induced breast growth.
How soon after a SARM cycle do people start PCT?
No study defines itEvidence: Limited
After five half-lives about 3% of a compound is left: roughly 5–8 days for LGD-4033 and 3–5 days for ostarine. A blood test taken earlier reflects the compound still in the body.
How long should you wait between SARM cycles?
Unknown; never testedEvidence: Human data
"Time on equals time off" is an untested rule of thumb. Hormones were back five weeks after a short, low-dose LGD-4033 course; after steroids, testosterone took about 3 months and sperm about a year.
Does natural PCT work?
Not shownEvidence: Limited
No natural PCT product has been tested after SARMs. A review of 50 testosterone boosters found only 24.8% had data supporting their claims.
Which blood tests show suppression?
Testosterone, LH, FSH, SHBGEvidence: Human data
Total testosterone (fasting, in the morning), LH, FSH, SHBG and free testosterone. The SARM studies also tracked HDL cholesterol, liver enzymes and bilirubin.
Sources
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study
- Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives
- Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study
- EMERALD study protocol (ISRCTN12213700, University of Liverpool, version 6.0, 2021): a window of opportunity study of enobosarm in ER+/AR+ early breast cancer
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report
- Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140
- A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
- Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use
- Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception (S-23, rats)
- Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats
- Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- Post-cycle therapy after short-term anabolic-androgenic steroid use: comparative outcomes in recreational bodybuilders
- EnCyzix (enclomifene): public assessment report, EMA/88321/2018
- Clomiphene Citrate in off-Label Post-Cycle Therapy: Mechanisms, Efficacy and Diagnostic Challenges in Endocrine Recovery Following Anabolic Steroid Use
- Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men
- Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
- World Anti-Doping Code International Standard: Prohibited List 2026
- Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels
- Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels
- FDA Denies Approval of Repros Therapeutics' Enclomiphene (BioSpace)
- EnCyzix | European Medicines Agency
- Drugs@FDA: CLOMID, NDA 016131
- Drugs@FDA: NOLVADEX, NDA 017970
- Drugs@FDA: ARIMIDEX, NDA 020541
- Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis
- CLOMID (clomiphene citrate) tablets – prescribing information (DailyMed)
- Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan)
- Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
- Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment
- Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males
- Safety and efficacy of enclomiphene and clomiphene for hypogonadal men
- Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
- FDA Pharmacy Compounding Advisory Committee transcript, June 8, 2022
- Elimination Half-Life of Drugs (StatPearls, NCBI Bookshelf)
- 'Testosterone Boosting' Supplements Composition and Claims Are not Supported by the Academic Literature
- trans-Resveratrol relaxes the corpus cavernosum ex vivo and enhances testosterone levels and sperm quality in vivo (rabbit tissue and mice)
- Efficacy of Furosap, a novel Trigonella foenum-graecum seed extract, in Enhancing Testosterone Level and Improving Sperm Profile in Male Volunteers
- Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects
- Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism
- Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study
- Gonadal steroids and body composition, strength, and sexual function in men
- Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review